NASDAQ$ZYME
Zymeworks Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Zymeworks reported Q4 2024 revenue of $76.3M.
For Q4 2024, Zymeworks reported Revenue was $76.3M. Management discusses segment trends, liquidity, and outlook in the quarterly filing.
- Revenue $76.3M for Q4 2024.
- MD&A highlights operating priorities, liquidity, and sector risks.
- MD&A highlights operating priorities, liquidity, and sector risks.
Headline financials
Revenue & EPS history
Zymeworks · Revenue · Quarterly
$76.3M
Forward guidance
Outlook emphasizes clinical milestones, cash runway, and R&D spend.
Tailwinds
- Pipeline progress and partnership optionality.
- Balance-sheet flexibility where noted.
Headwinds
- Operating losses until commercialization.
- Trial, regulatory, and financing risks.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 13 quarterly earnings reports · overlaid with Q4 2024
-1.2%
Avg return
Earnings day
-0.4%
Avg return
5 days after
+7.6%
Avg return
30 days after
38%
5 / 13 earnings
Positive
+1.4%
Q1 2023
Best reaction
-8.0%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.6% | -13.5% | -13.0% | |
| Q4 2025 | +0.1% | +3.4% | +11.4% | |
| Q3 2025 | -8.0% | +8.2% | +49.1% | |
| Q1 2025 | -0.1% | -0.6% | +11.3% | |
| Q4 2024 | -8.0% | -11.2% | -16.9% | |
| Q3 2024 | +1.0% | +1.2% | +11.7% | |
| Q2 2024 | +0.0% | +4.3% | +22.4% | |
| Q1 2024 | +0.0% | -8.3% | -18.4% | |
| Q4 2023 | +0.0% | +1.6% | +3.8% | |
| Q3 2023 | +1.2% | +0.1% | +31.2% | |
| Q3 2021 | +0.0% | -1.3% | +10.3% | |
| Q2 2023 | +0.8% | -3.6% | -7.5% | |
| Q1 2023 | +1.4% | +14.1% | +2.9% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro